Bliss GVS Pharma Ltd.
Snapshot View

109.30 -1.15 ▼-1.0%

27 July 2021, 04:00:00 P.M.
Volume: 11,159

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.blissgvs.com
Financial Indicators
Market Cap 1,141.58 Cr.
Earnings per share (EPS) 6.63 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 16.67 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 78.20 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.41 Calculated using Price: 110.45
Dividend Yield 0.45 Period Ending 2020-03
No. of Shares Subscribed 10.34 Cr. 103,357,172 Shares
FaceValue 1
Company Profile

Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.

It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.

Business area of the company

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Key Milestones

  • 1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
  • 1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
  • 2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
  • 2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
  • 2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
  • 2011: EU-GMP approval to the manufacturing facility for suppository facility.
  • 2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
  • 2017: Setting up offices in South East Asian countries.
  • 2018: Divestment from Bliss GVS Healthcare.
  • 2019: Setting up of multi-dosage facility (Vevoor Plant).

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.04%
1 Week
-0.32%
1 Month
-0.09%
3 Month
+4.05%
6 Month
-42.49%
1 Year
+3.31%
2 Year
-29.48%
5 Year
-4.83%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 27.85 25.56 15.17 19.74 26.73 25.06 17.34 21.43 13.79
Return on Capital Employed (%) 38.76 36.18 20.56 23.57 32.07 31.06 24.61 26.58 16.75
Return on Assets (%) 20.09 13.53 6.46 9.01 13.04 11.88 9.42 14.35 9.85

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 211 258 287 337 413 487 536 646 736
Non Curr. Liab. 39 97 96 68 50 33 13 38 46
Curr. Liab. 60 202 308 243 379 437 299 207 232
Minority Int. 14 10 15 33 66 11 14 15
Equity & Liab. 310 571 700 662 874 1,023 860 905 1,029
Non Curr. Assets 100 220 230 245 291 457 170 211 256
Curr. Assets 210 349 469 417 583 566 690 693 773
Misc. Exp. not W/O 2 1 0
Total Assets 310 571 700 662 874 1,023 860 905 1,029

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 267 397 345 407 547 798 815 899 689
Other Income 16 14 28 20 24 13 27 38 37
Total Income 283 411 373 427 571 811 841 936 726
Total Expenditure -196 -285 -273 -304 -391 -596 -618 -741 -566
PBIDT 87 125 99 124 180 215 224 195 160
Interest -4 -10 -18 -16 -19 -20 -23 -4 -5
Depreciation -4 -6 -11 -11 -13 -20 -21 -9 -13
Taxation -27 -50 -30 -35 -48 -63 -57 -55 -34
Exceptional Items -34 -13
PAT 53 60 41 61 100 113 89 127 95

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 35 7 41 38 113 289 18 40 45
Cash Fr. Inv. -22 -124 -11 -29 -50 -231 50 -74 -49
Cash Fr. Finan. 26 110 -8 -42 -40 -10 -76 17 -4
Net Change 40 -8 22 -33 23 48 -8 -17 -8
Cash & Cash Eqvt 58 50 50 5 28 47 37 15 15

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 41.53 41.53 41.60 41.60 41.60 41.60 33.31 33.31 33.24
Public 58.47 58.47 58.40 58.40 58.40 58.40 66.69 66.69 66.76
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.33 0.00 0.00 0.00

Announcements View Details

Fri, 23 Jul 2021
Board Meeting Intimation for Board Meeting Intimation For Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended June 30 2021
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2021 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company will be held on Saturday July 31 2021 at the registered office of the Company to consider and approve inter alia the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2021.

Further pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2021 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2021.
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 20 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0101
Name of the Signatory :- Aditi Bhatt
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Both SRS And ARS Below Zero Both SRS And ARS Below Zero
+DI Crossing -DI From Above +DI Crossing -DI From Above
ATR Decreasing for 3 Days ATR Decreasing for 3 Days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 688.00 -2.2%
Divi's Laboratories Ltd. 130,349.05 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. 90,021.63 4,844.35 -10.4%
Cipla Ltd. 76,675.40 913.20 -3.9%
Cadila Healthcare Ltd. 61,992.73 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,078.80 -0.5%
Aurobindo Pharma Ltd. 55,837.02 905.70 -5.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 4,844.35 -10.4%
Cipla Ltd. Consolidated 2021-03 31.88 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 905.70 -5.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 4,844.35 -10.4%
Cipla Ltd. Consolidated 2021-03 4.18 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 905.70 -5.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,844.35 -10.4%
Cipla Ltd. Consolidated 2020-03 0.18 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 905.70 -5.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,844.35 -10.4%
Cipla Ltd. Consolidated 2020-03 10.09 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 905.70 -5.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,844.35 -10.4%
Cipla Ltd. Consolidated 2020-03 12.53 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 905.70 -5.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,844.35 -10.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 905.70 -5.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 688.00 -2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,796.80 -2.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,844.35 -10.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 913.20 -3.9%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 598.90 -1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,078.80 -0.5%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 905.70 -5.0%